Three-month outcomes and cost-effectiveness of interferon gamma-1b in critically ill patients: a secondary analysis of the PREV-HAP trial
Early administration of interferon gamma might be cost-effective in critically ill patients supporting the realization of other studies on this treatment. However, the generalization of the findings should be considered cautiously, given the small sample size due to the premature end of PREV-HAP. Trial registration ClinicalTrials.gov Identifier: NCT04793568, Registration date: 2021-02-24.
Authors
- Philippe Tessier (ORCID: https://orcid.org/0000-0001-8324-1851)
- Cécile Poulain (ORCID: https://orcid.org/0009-0000-6169-5713)
- Antoine Roquilly (ORCID: https://orcid.org/0000-0002-1029-6242)
- Solène Schirr-Bonnans (ORCID: https://orcid.org/0000-0003-4591-6197)
- Marwan Bouras (ORCID: https://orcid.org/0000-0002-8335-5741)
Institutions
- Inserm (FR)
- The University of Melbourne (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Peter Doherty Institute (AU)
- Institut de Transplantation Urologie en Nephrologie (FR)
- Centre d'Investigation Clinique de Nantes (FR)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Hôpital Maison Blanche (FR)
- methodS in Patient-centered outcomes and HEalth ResEarch
- Nantes Université (FR)
Publication Details
- Journal
- Journal of Intensive Care
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1186/s40560-024-00753-z
- Citations
- 1
- Primary Topic
- Sepsis Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Horizon 2020 Framework Programme